Signal, buried.
Thousands of trials, abstracts and filings land every month. The one move that changes your strategy is in there — you just can't surface it in time.
COMPETITIVE INTELLIGENCE · ONCOLOGY-ONLY
Know the oncology landscape before it moves.
Prognyx turns the noise of trials, readouts, deals and regulatory moves into continuous, sourced, decision-ready intelligence — mapped around your pipeline, not a database you have to mine.
3,000+ trials watched
72h move-to-brief
1 focus — oncology
[ 01 ] THE PROBLEM
The field moves faster than any team can track.
Tools, not answers.
A six-figure database hands you data to mine. A consulting project hands you a deck — once. Neither watches your back on a Tuesday afternoon.
Priced for giants.
Enterprise intelligence is built for big-pharma budgets. The biotech with the most riding on a single asset is the one left flying blind.
0
oncology trials in motion, watched to the primary record
0
from competitor move to a brief on your desk
1
therapeutic focus — oncology, and nothing else
[ 02 ] WHAT PROGNYX DOES
Your competitive analyst, on continuous watch.
Not a portal you log into. Not a report you wait six weeks for. A standing intelligence function for your pipeline — reading every trial, readout, label and deal that touches your space, and telling you what it means and what to do.
- Continuous. The watch never stops between deliverables.
- Sourced. Every claim traces back to the primary record — NCT, label, abstract, filing.
- Decision-ready. The so-what and the now-what, not a data dump.
- Tailored. Scoped to your assets, mechanisms and indications.
COMPETITIVE BRIEF
LIVE WATCH
KRAS G12C — second-line NSCLC
Competitor readoutESMO 2026
Threat levelElevated
Window to act~6 weeks
78
A rival's confirmatory data lands before your filing. Here's the angle, the risk to your positioning, and the three moves on the table.
SOURCED · NCT05XXXXXX · ESMO abstract · FDA label
[ 03 ] HOW IT WORKS
From noise
to a decision,
in four moves.
Define
We map your competitive set — targets, mechanisms, indications and the assets that can move your value.
SCOPEWatch
We track trials, congress readouts, regulatory actions, deals and publications — straight to the primary source.
MONITORSynthesize
We turn it into what it means for you and what to do next — sharp, sourced, no filler.
ANALYZEDecide
You get briefs your team actually reads and forwards — plus answers on demand when the field shifts.
ACTThe next move,
first.
Start with a sample→
[ 04 ] WHY PROGNYX
Not a database. Not a $150k deck. Your analyst.
Prognyx
Data platforms
Consulting
Continuous watch
Tailored to your pipeline
Decision-ready (the so-what)
Oncology-deep
Days, not weeks
Accessible to a single-asset biotech
We don't out-database the giants. We out-matter them — on the one question they can't answer for you: what do I do about this, on my molecule, this week?
[ 05 ] FROM THE WATCHTOWER
Intelligence, in the open.
01
The KRAS G12C field after ESMO 2026
Who actually moved, who's exposed, and the readouts that will decide the next 12 months.
Read briefing →
02
ADCs in breast: who's really ahead
Cutting through the payload hype to the data that actually changes prescribing.
Read briefing →
03
Reading a Phase III readout before the press release
The signals in a registry update that tell you the result is already coming.
Read briefing →[ 06 ] THE OFFER
See the next move first.
Get a free sample competitive brief on one of your assets — sourced, sharp, no strings. If it's not the clearest read you've had on your space, you owe us nothing.
Request a sample brief→ONCOLOGY COMPETITIVE INTELLIGENCE · PROGNYX